寵物癌症藥物市場規模、佔有率和成長分析（按類型、治療方法、給藥途徑、癌症類型和地區分類）—2026-2033年產業預測

預計到 2024 年，寵物癌症藥物市場規模將達到 4.414 億美元，到 2025 年將達到 4.8466 億美元，到 2033 年將達到 10.2389 億美元，在預測期（2026-2033 年）內複合年成長率為 9.8%。

寵物癌症治療市場正經歷顯著成長，反映出人們對寵物醫療保健進步的日益關注。隨著寵物飼主越來越重視愛寵的健康，對有效癌症治療方法的需求也隨之增加。這一成長源於人們對寵物健康的日益重視，以及對提供最佳護理至關重要的認知。主要市場參與者正致力於研發專為寵物設計的創新治療方法，從而提高寵物確診後的生存率和生活品質。此外，獸醫腫瘤學的進步也加深了人們對寵物癌症的了解，並推動了標靶治療方案的發展。總而言之，該市場體現了關懷與科學創新的動態交匯，致力於滿足我們摯愛伴侶動物的特殊醫療保健需求。

寵物癌症藥物市場促進因素

推動寵物癌症治療市場成長的關鍵因素之一是寵物人性化趨勢的日益增強。隨著寵物飼主越來越將動物視為珍貴的家庭成員，他們也更願意投資先進的醫療保健方案，例如癌症治療。這種觀念的轉變正在推動對專為寵物設計的高效且人性化的癌症治療方法的需求。因此，這一趨勢正在促進行業創新並刺激市場擴張。各公司正致力於開發先進的解決方案，以滿足寵物飼主不斷變化的需求，幫助他們確保愛寵的健康和福祉。

寵物癌症藥物市場的限制

寵物癌症治療市場面臨的一大限制因素是寵物癌症治療帶來的沉重經濟負擔。包括診斷、手術、放射治療和藥物在內的各種醫療干預措施的高昂費用，可能會阻礙飼主為他們心愛的寵物尋求先進的治療方案。這種經濟負擔迫使許多飼主在他們願意提供的護理水平上做出艱難的抉擇，最終可能會阻礙寵物獲得可能挽救生命的治療。因此，儘管人們對這些治療方法的認知和需求都在不斷成長，但經濟承受能力問題仍然嚴重影響市場動態和有效治療方案的可近性。

寵物癌症治療市場趨勢

寵物癌症治療市場正呈現出顯著的趨勢，即採用個人化治療策略來滿足每隻寵物的獨特需求。飼主主人和獸醫越來越意識到不同動物物種的癌症類型和治療反應存在差異，這推動了對客製化治療方案的需求。診斷技術的創新，包括基因譜分析和分子檢測，為精準的癌症診斷奠定了基礎，並推動了針對每隻寵物癌症特徵的標靶治療的開發。這種轉變不僅提高了治療效果，還最大限度地減少了副作用，體現了獸醫腫瘤學領域致力於提升醫療品質和改善患者預後的堅定決心。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管分析

全球寵物癌症藥物市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 狗
• 貓
• 其他物種

全球寵物癌症藥物市場規模（按療法和複合年成長率分類）（2026-2033 年）

• 化療
• 免疫療法
• 標靶治療
• 聯合治療

全球寵物癌症藥物市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

• 口服
• 注射

全球寵物癌症治療市場規模（按癌症類型和複合年成長率分類）（2026-2033 年）

• 淋巴瘤
• 肥大細胞瘤
• 黑色素瘤
• 乳腺腺癌和鱗狀細胞癌
• 其他癌症

全球寵物癌症治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Elanco Animal Health（US）
• Anivive Lifesciences（US）
• Regeneus（Australia）
• Qbiotics（Australia）
• Zoetis（US）
• VetDC（US）
• AB Science（France）
• Vet Cancer Group（US）
• VetriScience（US）
• Vetnostics（Australia）
• Veterinary Cancer Society（US）
• PetCure Oncology（US）
• Oasmia Pharmaceutical（Sweden）

結論與建議

Pet Cancer Therapeutics Market size was valued at USD 441.4 Million in 2024 and is poised to grow from USD 484.66 Million in 2025 to USD 1023.89 Million by 2033, growing at a CAGR of 9.8% during the forecast period (2026-2033).

The pet cancer therapeutics market is experiencing significant growth, reflecting an increasing focus on advancements in pet healthcare. As pet owners prioritize their companions' health, there is rising demand for effective cancer treatment options. This surge is fueled by a heightened awareness of pet health and an understanding that providing optimal care is crucial. Key market players are innovating with new therapies designed specifically for pets, enhancing their chances of survival and quality of life post-diagnosis. Additionally, developments in veterinary oncology are enabling a deeper understanding of pet cancers, leading to the creation of targeted treatment solutions. Overall, the market represents a dynamic intersection of compassion and scientific innovation, addressing the specialized healthcare needs of cherished pets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pet Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pet Cancer Therapeutics Market Segments Analysis

Global Pet Cancer Therapeutics Market is segmented by Species, Therapy, Route of Administration, Cancer Type and region. Based on Species, the market is segmented into Dogs, Cats and Other species. Based on Therapy, the market is segmented into Chemotherapy, Immunotherapy, Targeted therapy and Combination therapy. Based on Route of Administration, the market is segmented into Oral and Injection. Based on Cancer Type, the market is segmented into Lymphoma, Mast cell cancer, Melanoma, Mammary and squamous cell cancer and Other cancer types. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pet Cancer Therapeutics Market

A significant factor propelling the growth of the pet cancer therapeutics market is the growing trend of pet humanization. As pet owners increasingly regard their animals as cherished family members, their readiness to invest in sophisticated healthcare options, such as cancer treatments, has intensified. This shift in perception has led to a heightened demand for effective and compassionate cancer therapies designed specifically for pets. Consequently, this trend fosters innovation within the industry and stimulates market expansion, as companies strive to develop advanced solutions that cater to the evolving needs of pet owners committed to ensuring the health and well-being of their beloved companions.

Restraints in the Pet Cancer Therapeutics Market

A notable limitation within the pet cancer therapeutics market is the considerable financial burden presented by cancer treatments for pets. The high costs associated with various medical interventions, such as diagnostics, surgical procedures, radiation therapy, and medications, can deter pet owners from pursuing advanced care options for their beloved animals. This financial strain may force many to make challenging decisions regarding the level of treatment they can provide, ultimately hindering their access to potentially life-saving therapies. Consequently, despite a growing awareness and demand for these therapeutics, the issue of affordability significantly influences market dynamics and the availability of effective treatments for pets.

Market Trends of the Pet Cancer Therapeutics Market

The pet cancer therapeutics market is experiencing a pronounced trend toward personalized treatment strategies that cater to the unique needs of individual pets. Pet owners and veterinarians are increasingly acknowledging the variance in cancer types and treatment responses among different animals, which is prompting a heightened demand for customized therapeutic solutions. Innovations in diagnostics, including genetic profiling and molecular testing, are paving the way for accurate cancer diagnoses, allowing for the development of targeted therapies that align with the specific characteristics of each pet's cancer. This shift not only enhances treatment efficacy but also minimizes adverse effects, demonstrating a robust commitment to improving care quality and patient outcomes in veterinary oncology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Analysis

Global Pet Cancer Therapeutics Market Size by Species & CAGR (2026-2033)

• Market Overview
• Dogs
• Cats
• Other species

Global Pet Cancer Therapeutics Market Size by Therapy & CAGR (2026-2033)

• Market Overview
• Chemotherapy
• Immunotherapy
• Targeted therapy
• Combination therapy

Global Pet Cancer Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injection

Global Pet Cancer Therapeutics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Lymphoma
• Mast cell cancer
• Melanoma
• Mammary and squamous cell cancer
• Other cancer types

Global Pet Cancer Therapeutics Market Size & CAGR (2026-2033)

• North America (Species, Therapy, Route of Administration, Cancer Type)
  • US
  • Canada
• Europe (Species, Therapy, Route of Administration, Cancer Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Species, Therapy, Route of Administration, Cancer Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Species, Therapy, Route of Administration, Cancer Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Species, Therapy, Route of Administration, Cancer Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Elanco Animal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anivive Lifesciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneus (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qbiotics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zoetis (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VetDC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AB Science (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vet Cancer Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VetriScience (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetnostics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veterinary Cancer Society (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PetCure Oncology (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oasmia Pharmaceutical (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations